1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,900 | 13,000 | 19:56 |
Chart-Typ:
Zeitraum:
| Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting | Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides... ► Artikel lesen |
| Oruka Therapeutics, Inc.: Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody | Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations | Fifth issued patent in the U.S. for QTORIN rapamycin with anticipated patent life extending into 2038 QTORIN rapamycin has the potential to be the first approved therapy and standard of care for microcystic... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Announces QTORIN Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology ... | Presentation highlighted the recent expansion of the Phase 3 SELVA trial to include children 3 to 5 years old Presentation reviewed clinically and statistically significant Phase 2 results and... ► Artikel lesen |
| Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical... ► Artikel lesen |
| XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.11.2024 | The following instruments on XETRA do have their first trading 20.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2024
Aktien
1 PLRNBWT00031 Rainbow Tours S.A.
2... ► Artikel lesen |
| Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen |
| Pre-market Movers: BTC Digital, XBP Europe, Neurogene, 1847 Holdings, Taysha Gene Therapies | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.00 A.M. ET).In the Green BTC Digital Ltd. (BTCT) is up over 78% at $4.50.
XBP... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.
